Presurgical Medical Treatment in Prolactinomas: Surgical Implications and Pathological Characteristics From 290 Cases
Authors' conclusion
This study described increased surgical difficulty and inferior endocrine outcomes associated with tumor fibrosis secondary to presurgical BRC treatment in prolactinomas. Neurosurgeons should note that presurgical BRC treatment may render subsequent surgery more challenging.
Study context
- Population
- Patients with prolactinomas treated by endoscopic endonasal surgery
- Participants
- 290 patients
- Exposure
- Presurgical dopamine agonist (DA) treatment vs initial surgery
- Outcome
- Tenacious tumor consistency
Methodological detailssingle-centre, Intratumoral collagen content assessed by Masson trichrome staining
- Single-centre
- Intratumoral collagen content assessed by Masson trichrome staining
Main finding
As reported in the abstract
P < 0.001
Observational data: associations, not effects.
Further findings
Intraoperative blood loss (macroadenomas)
P = 0.014
Surgical duration (macroadenomas)
P = 0.043
Collagen volume fraction (macroadenomas)
P = 0.001
Initial remission (microadenomas)
P = 0.047
Correlation of collagen volume fraction with cumulative bromocriptine (BRC) dose (macroadenomas)
- R
- 0.438, P < .001
Safety
Surgical morbidities (macroadenomas)
P = 0.034
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →